Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Why TEM stock sentiment could hinge on Tempus AI’s FDA-approved diagnostics expansion
Find out how Tempus AI’s xT CDx approval could strengthen TEM stock sentiment, oncology diagnostics growth, and ADLT pricing strategy.
Why Joenja’s pediatric expansion could strengthen Pharming Group’s long-term commercial runway
Find out how Pharming’s Joenja FDA review could affect PHAR stock sentiment, pediatric APDS access, and rare-disease revenue growth.
Lupin and Natco FDA approval puts #LUPIN in focus as oncology generic pipeline strengthens
Lupin and Natco won FDA approval for Eribulin generic. #LUPIN investors now face the real test: launch timing and U.S. pricing.
Why GILD stock sentiment may depend on more than one positive Phase 3 liver disease result
Find out why GILD stock sentiment may need more than positive Livdelzi data as investors weigh Gilead’s liver disease growth strategy.
AstraZeneca Pharma India exits factory licence as #ASTRAZEN investors assess asset-light model
AstraZeneca Pharma India surrendered its factory licence as #ASTRAZEN exits manufacturing. Find out what the shift means for investors.
Elementis exits pharmaceutical manufacturing as $ELM shifts capital toward Personal Care and Coatings
Elementis sells its Pharma business and plans a $35m buyback. Find out how the $ELM portfolio reset could reshape investor sentiment.
Legend Biotech soars 42% on ASCO data as CAR-T momentum extends from blood cancers toward solid tumors
Legend Biotech soared 42% on ASCO data: a survival readout for myeloma CAR-T CARVYKTI plus early solid-tumor results for LB2102. Big ramp, but still loss-making.
Moderna (MRNA) and Merck (MRK) cancer vaccine sustains benefit at five years, but investors stay cautious
Moderna and Merck's mRNA cancer vaccine sustained a 49% reduction in melanoma recurrence at five years, but MRNA fell as investors weigh near-term pressures.
Eli Lilly (LLY) reclaims a $1tn valuation as Wall Street bets on its next weight-loss drug
Eli Lilly reclaimed a $1 trillion valuation at a record high as Wall Street prices in retatrutide, its next-gen obesity drug, and the GLP-1 metabolic platform thesis.
Has Akeso Inc. just exposed the next weak spot in standard lung cancer treatment?
Find out how Akeso Inc.’s ivonescimab survival data could reshape lung cancer treatment and challenge PD-1 drug combinations.